Colonic cells

Colonic cells, which include colonocytes, goblet cells, and enteroendocrine cells, form the mucosal epithelium of the large intestine and are vital for the absorption of water and electrolytes from luminal contents [StatPearls: PMID 31082012]. They establish a critical physical and immunological barrier that separates the systemic environment from the complex gut microbiota [NCBI: PMC5102559]. Dysfunction or malignant transformation of these cells leads to significant pathologies, most notably colorectal cancer and inflammatory bowel diseases (IBD) such as ulcerative colitis [PubMed: 28548130]. While various therapeutic agents, including aminosalicylates, corticosteroids, and monoclonal antibodies, are utilized to treat colonic disorders, they typically act upon specific molecular mediators like TNF-alpha or cellular pathways rather than the cell as a whole [NIH: LiverTox]. Because colonic cells represent a heterogeneous cell population and a biological site rather than a single molecule, they are classified as a tissue or cell type rather than a specific therapeutic target. Consequently, drug development focuses on identifying specific receptors or enzymes expressed by these cells to achieve localized or systemic therapeutic effects.

Other names

ColonocytesColonic epithelial cellsLarge intestine cellsIntestinal epithelial cells of the colon

Drugs targeting diseases of the colonic cells act via diverse mechanisms, including the inhibition of cyclooxygenase and lipoxygenase (Mesalamine), neutralization of pro-inflammatory cytokines (Infliximab), or inhibition of thymidylate synthase to arrest cell division in malignancies (Fluorouracil).